Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older AML Patients With NPM1 Mutation
DRKS00000783Phase 3Active, not recruiting
- Sponsor
- Ulm University
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of cytarabine, etoposide and tretinoin in acute myeloid leukemia (AML) (2 arms), sponsored by Ulm University. Started Apr 2011; status: active, not recruiting.
02
Drugs
cytarabineetoposidetretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00000783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000783.